Loading cancer entity…
Loading cancer entity…
Clinical trials
79 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | completed | Phase 1 | 22 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03295227 | Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer | recruiting | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04375267 |
| 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours(LuPARP) |
| completed |
| Phase 1 |
| 18 |
| Vastra Gotaland RegionOTHER_GOV |
| 1 |
| Apr 14, 2026 |
| clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04371458 | Thymectomy With and Without Povidone-iodine Pleural Lavage in Stage IVA Thymic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Yale UniversityOTHER | 0 | Jul 25, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT00921739 | Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies(ESIMRT) | completed | Phase 1 | 24 | Duke UniversityOTHER | 1 | Apr 2, 2020 | clinicaltrials |
| NCT01258868 | Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas | terminated | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2019 | clinicaltrials |
| NCT01100944 | A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies | terminated | Phase 1 / Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2017 | clinicaltrials |
Data updated 12 hours agoSource updated Sep 29, 2026source: clinicaltrials